FMT
SRPT icon

First Mercantile Trust’s Sarepta Therapeutics SRPT Stock Holding History

First Mercantile Trust’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$103K Sell
1,116
-116
-9% -$8.94K 0.01% 650
2021
Q2 		$96K Buy
+1,232
New +$93.4K 0.01% 696
2017
Q4 		– Sell
-1,669
Closed -$76K – 830
2017
Q3 		$76K Buy
+1,669
New +$66.7K 0.01% 742

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Mercantile Trust's SRPT Position: Q3 2021 in Review

First Mercantile Trust reduced its Sarepta Therapeutics (SRPT) stake by 9.4% in Q3 2021, selling an estimated $8.94K and leaving 1,116 shares worth $103K. The position accounts for 0.01% of the portfolio, ranked #650.

First Mercantile Trust first reported a position in SRPT in Q3 2017 and has held it in 3 quarters since. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • First Mercantile Trust held 1,116 shares of Sarepta Therapeutics worth $103K as of Q3 2021.
  • First Mercantile Trust sold 116 Sarepta Therapeutics shares in Q3 2021, an estimated $8.94K.
  • Sarepta Therapeutics made up 0.01% of First Mercantile Trust's portfolio in Q3 2021, its #650 holding.
  • First Mercantile Trust first reported a position in Sarepta Therapeutics in Q3 2017 and has held it in 3 quarters since.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on First Mercantile Trust's 13F filing for Q3 2021, filed 24 Nov 2021.